Develop non-invasive, real-time monitoring and diagnostic tests. Create saliva-based glucose biosensors for diabetes management. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 0.3× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 35% of them.
No analyst target is on record for this company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Business Quality: Profit power and business quality trail similar companies in the sector.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $4.2M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 11 buys and 1 sell. Management buying with its own money is usually read as a good sign.
A loss of $12.4M against $4.2M in annual sales.
This stock swings about 4.2 times as much as the market average. Big rallies — and big drops — can both happen fast.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, INBS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: INBS is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Not covered, because the filings we hold do not carry it: the revenue breakdown.